Literature DB >> 23261681

RETRACTED: Bezafibrate improves mitochondrial function in the CNS of a mouse model of mitochondrial encephalopathy.

Natalie Noe1, Lloye Dillon, Veronika Lellek, Francisca Diaz, Aline Hida, Carlos T Moraes, Tina Wenz.   

Abstract

This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This retraction was suggested by the University of Cologne Investigation committee and seconded by the authors who the journal was able to contact (Wenz, T., Dillon, L., Diaz, F., Hida, A., and Moraes, C.T.). Following an investigation of the last author, Dr. Tina Wenz, by the University of Cologne, Germany, the university determined that data presented in this article have been inappropriately manipulated https://www.portal.uni-koeln.de/9015.html?&tx_news_pi1%5Bnews%5D=4335&tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=1deb8399d7f796d65ca9f6ae4764a1ce. Specifically, western blot images in Figure 5F (tubulin in cortex), 2F (COXI in hippocampus) and 3B (Sod2 in hippocampus) were re-used from an earlier article published elsewhere [Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging" Wenz T, Rossi SG, Rotundo RL, Spiegelman BM, and Moraes CT. Proc Natl Acad Sci U S A. 2009;106:20405-10, doi: 10.1073/pnas.0911570106] representing different experimental findings. Therefore, whether or not the main conclusions are still valid, the authors request retraction of this publication because the scientific integrity of the study was compromised. The authors sincerely apologize to the scientific community.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bezafibrate; CNS; Mitochondrial encephalopathy; PPAR/PGC-1α

Mesh:

Substances:

Year:  2012        PMID: 23261681      PMCID: PMC3755107          DOI: 10.1016/j.mito.2012.12.003

Source DB:  PubMed          Journal:  Mitochondrion        ISSN: 1567-7249            Impact factor:   4.160


  41 in total

Review 1.  Transcriptional paradigms in mammalian mitochondrial biogenesis and function.

Authors:  Richard C Scarpulla
Journal:  Physiol Rev       Date:  2008-04       Impact factor: 37.312

2.  Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators.

Authors:  Julie St-Pierre; Stavit Drori; Marc Uldry; Jessica M Silvaggi; James Rhee; Sibylle Jäger; Christoph Handschin; Kangni Zheng; Jiandie Lin; Wenli Yang; David K Simon; Robert Bachoo; Bruce M Spiegelman
Journal:  Cell       Date:  2006-10-20       Impact factor: 41.582

3.  Neuroprotection by resveratrol against traumatic brain injury in rats.

Authors:  Ozkan Ates; Suleyman Cayli; Eyup Altinoz; Iclal Gurses; Neslihan Yucel; Metin Sener; Ayhan Kocak; Saim Yologlu
Journal:  Mol Cell Biochem       Date:  2006-08-19       Impact factor: 3.396

Review 4.  PGC-1alpha, a new therapeutic target in Huntington's disease?

Authors:  Jetta K McGill; M Flint Beal
Journal:  Cell       Date:  2006-11-03       Impact factor: 41.582

5.  Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease.

Authors:  Ashu Johri; Noel Y Calingasan; Thomas M Hennessey; Abhijeet Sharma; Lichuan Yang; Elizabeth Wille; Abhishek Chandra; M Flint Beal
Journal:  Hum Mol Genet       Date:  2011-11-17       Impact factor: 6.150

6.  PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss.

Authors:  Gianluca Miglio; Arianna C Rosa; Lorenza Rattazzi; Massimo Collino; Grazia Lombardi; Roberto Fantozzi
Journal:  Neurochem Int       Date:  2009-05-13       Impact factor: 3.921

Review 7.  PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure.

Authors:  Carles Cantó; Johan Auwerx
Journal:  Curr Opin Lipidol       Date:  2009-04       Impact factor: 4.776

8.  PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice.

Authors:  Michael J Ryan; Sean P Didion; Satya Mathur; Frank M Faraci; Curt D Sigmund
Journal:  Hypertension       Date:  2004-01-26       Impact factor: 10.190

9.  PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons.

Authors:  Przemyslaw Wareski; Annika Vaarmann; Vinay Choubey; Dzhamilja Safiulina; Joanna Liiv; Malle Kuum; Allen Kaasik
Journal:  J Biol Chem       Date:  2009-06-19       Impact factor: 5.157

10.  Long-term bezafibrate treatment improves skin and spleen phenotypes of the mtDNA mutator mouse.

Authors:  Lloye M Dillon; Aline Hida; Sofia Garcia; Tomas A Prolla; Carlos T Moraes
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

View more
  22 in total

Review 1.  Mitochondrial Diseases Part III: Therapeutic interventions in mouse models of OXPHOS deficiencies.

Authors:  Susana Peralta; Alessandra Torraco; Luisa Iommarini; Francisca Diaz
Journal:  Mitochondrion       Date:  2015-01-29       Impact factor: 4.160

Review 2.  Therapies for mitochondrial diseases and current clinical trials.

Authors:  Ayman W El-Hattab; Ana Maria Zarante; Mohammed Almannai; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2017-09-18       Impact factor: 4.797

3.  Bezafibrate In Vivo Administration Prevents 3-Methylglutaric Acid-Induced Impairment of Redox Status, Mitochondrial Biogenesis, and Neural Injury in Brain of Developing Rats.

Authors:  Nevton Teixeira da Rosa-Junior; Belisa Parmeggiani; Mateus Struecker da Rosa; Nícolas Manzke Glänzel; Leonardo de Moura Alvorcem; Moacir Wajner; Guilhian Leipnitz
Journal:  Neurotox Res       Date:  2019-03-09       Impact factor: 3.911

Review 4.  Advances in drug therapy for mitochondrial diseases.

Authors:  Lufei Zhang; Zhaoyong Zhang; Aisha Khan; Hui Zheng; Chao Yuan; Haishan Jiang
Journal:  Ann Transl Med       Date:  2020-01

Review 5.  Emerging therapies for mitochondrial diseases.

Authors:  Michio Hirano; Valentina Emmanuele; Catarina M Quinzii
Journal:  Essays Biochem       Date:  2018-07-20       Impact factor: 8.000

6.  MTO1 mediates tissue specificity of OXPHOS defects via tRNA modification and translation optimization, which can be bypassed by dietary intervention.

Authors:  Christin Tischner; Annette Hofer; Veronika Wulff; Joanna Stepek; Iulia Dumitru; Lore Becker; Tobias Haack; Laura Kremer; Alexandre N Datta; Wolfgang Sperl; Thomas Floss; Wolfgang Wurst; Zofia Chrzanowska-Lightowlers; Martin Hrabe De Angelis; Thomas Klopstock; Holger Prokisch; Tina Wenz
Journal:  Hum Mol Genet       Date:  2014-12-30       Impact factor: 6.150

Review 7.  Autophagy of mitochondria: a promising therapeutic target for neurodegenerative disease.

Authors:  Pradip K Kamat; Anuradha Kalani; Philip Kyles; Suresh C Tyagi; Neetu Tyagi
Journal:  Cell Biochem Biophys       Date:  2014-11       Impact factor: 2.194

Review 8.  Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models.

Authors:  J C Komen; D R Thorburn
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

9.  Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.

Authors:  Abhishek Chandra; Abhijeet Sharma; Noel Y Calingasan; Joshua M White; Yevgeniya Shurubor; X William Yang; M Flint Beal; Ashu Johri
Journal:  Hum Mol Genet       Date:  2016-03-22       Impact factor: 6.150

10.  Treatment of mitochondrial disorders.

Authors:  Sreenivas Avula; Sumit Parikh; Scott Demarest; Jonathan Kurz; Andrea Gropman
Journal:  Curr Treat Options Neurol       Date:  2014-06       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.